GH SecretagoguesFDA ApprovedS

Tesamorelin

Egrifta

Tesamorelin (brand: Egrifta SV) is the only FDA-approved GHRH analog, indicated for reduction of excess visceral abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Phase III clinical trials demonstrated significant visceral adipose tissue (VAT) reduction, improved triglyceride profiles, and increased IGF-1 at 2 mg daily dosing. Available by prescription through specialty pharmacies and telehealth.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
59

Trend index

Trackers
693

Overview

About Tesamorelin

Tesamorelin (brand: Egrifta SV) is the only FDA-approved GHRH analog, indicated for reduction of excess visceral abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Phase III clinical trials demonstrated significant visceral adipose tissue (VAT) reduction, improved triglyceride profiles, and increased IGF-1 at 2 mg daily dosing. Available by prescription through specialty pharmacies and telehealth.

Category
GH Secretagogues
Regulatory status
FDA Approved
Also known as
Egrifta
Self-reports
114

Community

What 114 users report

114 community reports

Positive 3% · Neutral 97% · Negative 0%

Most reported benefits

Appetite
224
Sleep
1
Recovery
1
Libido
1

Most reported side effects

Injection site irritation
113
Water retention
106

Dose distribution

Median: 1000–2000 mcg · Most common: 1000–2000 mcg

0–25
9
25–50
0
50–100
0
100–200
1
200–400
5
400–600
5
600–1000
4
1000–2000
126
2000+
75

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 46 days · Based on 41 repeat reporters

Research

Cited research (2)

Help

Frequently asked

What do PeptIQ users report about Tesamorelin?

This page summarizes 114 anonymized self-reports from PeptIQ users who track Tesamorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Tesamorelin?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Tesamorelin safe to use?

This wiki does not assess safety or recommend use. Tesamorelin is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Tesamorelin?

Research, primarily in animal models, suggests Tesamorelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Tesamorelin?

Tesamorelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Tesamorelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Tesamorelin?

The safety and effectiveness of Tesamorelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Tesamorelin?

While there are over 200 published studies on Tesamorelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source